Gianpiero Fasola

List of Publications by Year
in descending order

135	3,059	186254	189881
papers	citations	28 h-index	50 g-index

137	137	137	5128
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2014, 32, 2240-2247.	1.6	573
2	Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist, 2014, 19, 608-615.	3.7	205
3	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wildâ€type <scp>KRAS</scp> advanced biliary tract cancer: A randomized phase 2 trial (<scp>V</scp>ectiâ€«<scp>BIL</scp> study). Cancer, 2016, 122, 574-581.	4.1	121
4	Clinical advances in the development of novel VEGFR2 inhibitors. Annals of Translational Medicine, 2014, 2, 123.	1.7	121
5	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease, 2017, 32, 1179-1190.	2.2	96
6	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trialâ€”An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist, 2007, 12, 1215-1224.	3.7	82
7	Italian Nivolumab Expanded Access Program inÂNonsquamous Nonâ€“Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	1.1	77
8	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. Oncologist, 2009, 14, 497-510.	3.7	64
9	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 368-377.	7.3	61
10	Drug waste minimization as an effective strategy of cost-containment in Oncology. BMC Health Services Research, 2014, 14, 57.	2.2	58
11	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	6.4	56
12	Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study. BMC Health Services Research, 2008, 8, 70.	2.2	54
13	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1458-1467.	1.1	50
14	Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumor Biology, 2013, 34, 131-137.	1.8	49
15	Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncology, 2015, 11, 629-640.	2.4	49
16	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: AÂpropensity score analysis. Breast, 2017, 31, 114-120.	2.2	49
17	Treatment of Metastatic Breast Cancer in a Realâ€World Scenario: Is Progressionâ€Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Oncologist, 2015, 20, 719-724.	3.7	46
18	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46

#	Article	IF	Citations
19	Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. Journal of Cancer Research and Clinical Oncology, 2009, 135, 451-457.	2.5	42
20	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 2019, 11, 1243.	3.7	40
21	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. Journal of Cancer Research and Clinical Oncology, 2017, 143, 783-791.	2.5	36
22	Serum LDH Concentration in Non-Hodgkinâ€™s Lymphomas. Acta Haematologica, 1984, 72, 231-238.	1.4	35
23	Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems. BMC Health Services Research, 2013, 13, 522.	2.2	34
24	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2008, 68, 183-196.	4.4	33
25	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
26	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer, 2020, 140, 59-64.	2.0	33
27	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opinion on Investigational Drugs, 2014, 23, 925-942.	4.1	32
28	Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anti-Cancer Drugs, 2009, 20, 503-507.	1.4	29
29	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
30	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. Future Oncology, 2018, 14, 699-707.	2.4	29
31	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	1.1	28
32	Factors affecting patient's perception of anticancer treatments side-effects: an observational study. Expert Opinion on Drug Safety, 2014, 13, 139-150.	2.4	26
33	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Critical Reviews in Oncology/Hematology, 2015, 95, 165-178.	4.4	26
34	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	3.2	25
35	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). Journal of Thoracic Oncology, 2010, 5, 1354-1360.	1.1	24
36	Adopting Integrated Care Pathways in Nonâ€“Small-Cell Lung Cancer: From Theory to Practice. Journal of Thoracic Oncology, 2012, 7, 1283-1290.	1.1	21

#	Article	IF	Citations
37	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. Oncologist, 2020, 25, 661-668.	3.7	21
38	Prognostic evaluation in palliative care: final results from a prospective cohort study. Supportive Care in Cancer, 2019, 27, 2095-2102.	2.2	20
39	Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 331-342.	2.4	19
40	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clinical Colorectal Cancer, 2018, 17, e457-e470.	2.3	18
41	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	3.3	18
42	Emerging therapies in malignant pleural mesothelioma. Critical Reviews in Oncology/Hematology, 2019, 144, 102815.	4.4	17
43	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Pagetâ€™s disease of the vulva. International Journal of Gynecological Cancer, 2020, 30, 1672-1677.	2.5	17
44	Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. Supportive Care in Cancer, 2014, 22, 2527-2533.	2.2	16
45	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. International Journal of Epidemiology, 2018, 47, 1981-1991.	1.9	16
46	MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. Future Oncology, 2015, 11, 1201-1209.	2.4	15
47	Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells. Cancers, 2018, 10, 270.	3.7	15
48	Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report. BMC Cancer, 2006, 6, 289.	2.6	14
49	Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Research and Treatment, 2007, 105, 133-138.	2.5	14
50	Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. Anti-Cancer Drugs, 2012, 23, 326-334.	1.4	14
51	Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome. Critical Reviews in Oncology/Hematology, 2013, 85, 32-44.	4.4	14
52	HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. International Journal of Molecular Sciences, 2013, 14, 2370-2387.	4.1	14
53	Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?. OncoTargets and Therapy, 2014, 7, 1783.	2.0	14
54	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	1.8	14

#	Article	IF	Citations
55	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. Future Oncology, 2018, 14, 849-859.	2.4	14
56	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.	2.2	14
57	A Model to Estimate Human Resource Needs for the Treatment of Outpatients With Cancer. Journal of Oncology Practice, 2012, 8, 13-17.	2.5	13
58	Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. Melanoma Research, 2013, 23, 96-101.	1.2	13
59	PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wildâ€'type (WT) KRAS metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2013, 31, 446-446.	1.6	13
60	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer, 2006, 52, 89-92.	2.0	12
61	ABOUND.2L+: A randomized phase 2 study of nanoparticle albuminâ€bound paclitaxel with or without CCâ€486 as secondâ€line treatment for advanced nonsquamous nonâ€small cell lung cancer (NSCLC). Cancer, 2018, 124, 4667-4675.	4.1	12
62	Prognostic role of disease extent and lymphocyteâ€“monocyte ratio in advanced melanoma. Melanoma Research, 2019, 29, 510-515.	1.2	12
63	Immunotherapy in NSCLC Patients with Brain Metastases. International Journal of Molecular Sciences, 2022, 23, 7068.	4.1	12
64	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 2004, 46, 99-106.	2.0	11
65	Anticancer drugs and central nervous system: Clinical issues for patients and physicians. Cancer Letters, 2008, 267, 1-9.	7.2	11
66	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. British Journal of Cancer, 2019, 120, 522-526.	6.4	11
67	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. Annals of Translational Medicine, 2019, 7, 14-14.	1.7	11
68	Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncology, 2017, 13, 135-144.	2.4	9
69	Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2029-2047.	2.5	9
70	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. Journal of Neuro-Oncology, 2018, 140, 559-568.	2.9	9
71	First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.. Journal of Clinical Oncology, 2015, 33, 660-660.	1.6	9
72	Relationship of serum lactate dehydrogenase level with first remission length in adult acute lymphocytic leukaemia. British Journal of Haematology, 1987, 66, 49-53.	2.5	8

#	Article	IF	Citations
73	Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 205-213.	2.4	8
74	Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. Melanoma Research, 2018, 28, 547-554.	1.2	8
75	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Current Drug Targets, 2017, 18, 341-362.	2.1	8
76	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431.	3.7	7
77	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. European Journal of Cancer, 2021, 148, 112-116.	2.8	7
78	Cell kinetic effect of low dose arabinosyl cytosine. British Journal of Haematology, 1987, 67, 33-37.	2.5	6
79	Bone Scan for Baseline Staging in Invasive Breast Cancer at the Time of Primary Presentation. Breast Care, 2007, 2, 358-364.	1.4	6
80	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpeâ€“Adria Thoracic Oncology Multidisciplinary group trial (ATOM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	6
81	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 2020, 11, 1268-1273.	1.0	6
82	Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy. Journal of Cancer Policy, 2021, 29, 100297.	1.4	6
83	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	2.0	5
84	INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT. International Journal of Technology Assessment in Health Care, 2018, 34, 3-9.	0.5	5
85	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	3.7	5
86	Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3629-3629.	1.6	5
87	Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage?. World Journal of Gastroenterology, 2013, 19, 2131.	3.3	5
88	Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) + either panitumumab (pmab) or bevacizumab (bev).. Journal of Clinical Oncology, 2015, 33, 3535-3535.	1.6	5
89	Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution. Journal of Clinical Oncology, 2015, 33, 3841-3842.	1.6	4
90	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1185-1198.	4.1	4

#	Article	IF	Citations
91	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer, 2019, 134, 121-126.	2.0	4
92	Effectiveness and Toxicity of Â«BeldÂ» Polychemotherapy in Advanced Malignant Melanoma. Tumori, 1989, 75, 229-232.	1.1	3
93	Maintenance treatment of multiple myeloma. European Journal of Haematology, 1989, 43, 145-151.	2.2	3
94	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. Clinical Colorectal Cancer, 2016, 15, 7-15.	2.3	3
95	Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID â€19 Pandemic. Oncologist, 2021, 26, e694-e703.	3.7	3
96	Impact of innovation in oncology: more questions than answers. Tumori, 2021, 107, 478-482.	1.1	3
97	Infections in Patients with Acute Non-Lymphocytic Leukemia Nursed with Central or Peripheral Venous Access. Tumori, 1993, 79, 112-115.	1.1	2
98	Comment on: â€œLow-dose computed tomography screening for lung cancer in people with workplace exposure to asbestosâ€. Lung Cancer, 2019, 136, 150.	2.0	2
99	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	2.4	2
100	A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.. Journal of Clinical Oncology, 2015, 33, 281-281.	1.6	2
101	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. Journal of Clinical Oncology, 2018, 36, e13079-e13079.	1.6	2
102	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
103	Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave. PLoS ONE, 2022, 17, e0262784.	2.5	2
104	A Phase II Study of Mitoxantrone. Tumori, 1988, 74, 579-583.	1.1	1
105	Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example. OncoTargets and Therapy, 2016, Volume 9, 5399-5404.	2.0	1
106	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 2020, 16, 2645-2660.	2.4	1
107	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs and Aging, 2020, 37, 677-689.	2.7	1
108	The impact of COVID-19 pandemic on oncology workload: The experience of an Italian Reference Cancer Center.. Journal of Clinical Oncology, 2021, 39, e13520-e13520.	1.6	1

#	Article	IF	Citations
109	Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts): A retrospective study.. Journal of Clinical Oncology, 2014, 32, 511-511.	1.6	1
110	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e24014-e24014.	1.6	1
111	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Research, 2015, 35, 2391-9.	1.1	1
112	Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?. Frontiers in Oncology, 0, 12, .	2.8	1
113	In vitro exposure of leukemic cells to low concentration arabinosyl cytosine: No evidence of differentiation inducing activity. Blut, 1987, 54, 299-306.	1.2	0
114	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. Journal of Clinical Oncology, 2012, 30, e13070-e13070.	1.6	0
115	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, e13058-e13058.	1.6	0
116	Association of body mass index and outcome in advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 1044-1044.	1.6	0
117	Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)?. Journal of Clinical Oncology, 2012, 30, 3612-3612.	1.6	0
118	Cancer of unknown primary origin: a case report. Clinical Management Issues, 2013, 7, 27-34.	0.3	0
119	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. Journal of Clinical Oncology, 2014, 32, e22006-e22006.	1.6	0
120	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. Journal of Clinical Oncology, 2014, 32, e11524-e11524.	1.6	0
121	Prognostic characterization in the terminal phase of cancer: May clinical prediction be improved?. Journal of Clinical Oncology, 2015, 33, e20507-e20507.	1.6	0
122	Endocrine maintenance therapy in luminal breast cancer.. Journal of Clinical Oncology, 2015, 33, e11578-e11578.	1.6	0
123	Treatment during the last month of life in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, e17649-e17649.	1.6	0
124	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e11573-e11573.	1.6	0
125	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. Journal of Clinical Oncology, 2016, 34, 342-342.	1.6	0
126	Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.. Journal of Clinical Oncology, 2016, 34, e21601-e21601.	1.6	0

#	Article	IF	Citations
127	Anxiety, depression in lung cancer and the predictive role of unmet needs: Data from a national multicenter study (E-LUNG).. Journal of Clinical Oncology, 2016, 34, 10062-10062.	1.6	0
128	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. Journal of Clinical Oncology, 2016, 34, 1554-1554.	1.6	0
129	Setting and timing of end-of-life care in cancer patients.. Journal of Clinical Oncology, 2017, 35, e21502-e21502.	1.6	0
130	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. Journal of Clinical Oncology, 2017, 35, e12010-e12010.	1.6	0
131	A novel MGMT methylation-based prognostic score in patients with glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2048-2048.	1.6	0
132	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€"Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	1.6	0
133	Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology.. Journal of Clinical Oncology, 2018, 36, e18865-e18865.	1.6	0
134	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	1.6	0
135	Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy. , 2020, , .		0